Bacteria thya(-) mutants with increased vitamin k

Abstract

Bacteria thyA(−) mutants with increased vitamin K and use of these thyA(−) mutants for making a composition/product for treatment and/or prevention of vitamin K deficiency in a mammal (e.g. a human).

1 . A composition comprising bacteria containing vitamin K2, wherein the amount of bacteria present in the composition results in:
 (a): at least 0.10 μg/(ml or g) of vitamin K2 in the composition;
 and wherein
 (i): the bacteria are thyA(−) mutants; and 
 (ii): the bacteria are bacteria selected from the group consisting of the genera:  Lactococcus, Leuconostoc  and  Bacillus;    
 
 and wherein the composition is for use for treatment and/or prevention of vitamin K deficiency in a mammal. 
   
     
     
         2 . The composition of  claim 1 , wherein the composition is a food product. 
     
     
         3 . The composition of  claim 2 , wherein the food product is animal milk fermented with thyA(−) bacteria. 
     
     
         4 . The composition of  claim 3 , wherein the dairy product is at least one dairy product selected from the list consisting of: milk, yogurt and cheese. 
     
     
         5 . The composition of  claim 3 , wherein the animal fermented milk is obtained by
 (A): inoculating from 10 8  to 10 12  cfu/ml of thyA(−) bacteria of  claim 1  to the animal milk; and   (B): fermenting the milk from 4 to 72 hours at a temperature from 10° C. to 50° C.   
     
     
         6 . The composition of  claim 1 , wherein the composition is a composition comprising dried isolated thyA(−) mutant bacteria of  claim 1  and it is a medicament. 
     
     
         7 . The composition of  claim 1 , wherein the bacteria are  Lactococcus lactis.    
     
     
         8 . The composition of  claim 7 , wherein the  Lactococcus lactis  bacteria are  Lactococcus lactis  subsp.  lactis  or  Lactococcus lactis  subsp.  cremoris.    
     
     
         9 . The composition of  claim 8 , wherein the bacteria are the thyA(−)  Lactococcus lactis  subsp.  lactis  mutant strain MBP71 deposited under the accession number DSM12891. 
     
     
         10 . The composition of  claim 1 , wherein the composition of  claim 1  comprises from 10 8  to 10 12  cfu/(ml or mg) of the thyA(−) bacteria of  claim 1 . 
     
     
         11 . The composition of  claim 1 , wherein mammal is a human. 
     
     
         12 . The composition of  claim 11 , wherein the treatment and/or prevention of vitamin K deficiency is for improving bone health in a human. 
     
     
         13 . The composition of  claim 12 , wherein the improvement of bone health is related to less malformation of developing bone or bone strength. 
     
     
         14 . The composition of  claim 1 , wherein there in point (a) of  claim 1  is at least 0.10 μg/mg of vitamin K2 in the composition.